Randomized controlled trials (RCTs) have established that carotid endarterectomy (CEA) is superior to medical therapy in preventing stroke in both asymptomatic and symptomatic patients with carotid stenosis. However, while the majority of patients who undergo carotid revascularization receive treatment for asymptomatic disease, the benefit of revascularization for patients with asymptomatic disease is quite modest. In addition, the clinical trials were initiated about 20 years ago, and in the intervening period, medical therapy has greatly improved for this vascular disease due to new pharmacological advances such as high potency statins, improved antiplatelet regimens, and better control of hypertension, hyperlipidemia and diabetes. In parallel, as the surgical complication rate for CEA has decreased, the use of carotid artery stenting (CAS) has been gaining favor in the treatment of asymptomatic carotid stenosis. While recent trials have focused exclusively on comparing CEA to CAS, the declining stroke rate associated with medically managed carotid stenosis has led many to question whether either revascularization procedure is superior to aggressive vascular risk factor control. A three-arm RCT could answer this question, but such a study would be very expensive, not provide answers for a long time, and might only enroll the subset of healthiest patients typically studied in an RCT. Since the first RCT was published that demonstrated the superiority of CEA compared to medical therapy there has been a concern that the modest benefit observed in the trials may not be reproducible in the community. To address the ongoing debate of whether among patients with asymptomatic carotid stenosis, CEA is still superior to medical therapy and whether CAS is superior to medical therapy (which has never been evaluated in an RCT), we propose to examine the comparative effectiveness of initial medical therapy compared to early carotid intervention in a retrospective cohort study of 6000 patients using merged Veteran's Health Administration and Medicare data. We will specifically compare each revascularization strategy to medical therapy and also examine the impact of a number of key variables (e.g. age, presence of atrial fibrillation) on the comparative effectiveness of intervention compared to medical therapy. We will use advanced statistical techniques to overcome observed and unobserved differences in the medical therapy and intervention cohorts. We will compare the 30-day and 5 year outcomes of 3175 patients managed medically, 1500 patients who received CEA, and 1325 patients who received CAS entering the cohort from 2005 to 2008. Our overarching hypothesis is that medical therapy has improved to a degree that only certain subgroups of patients may benefit from revascularization and that for many patients medical therapy may be the preferred treatment strategy.

Public Health Relevance

The reported declining stroke rate among patients with asymptomatic carotid stenosis may have changed the risk benefit ratio of carotid revascularization. Medical therapy may now be the preferred treatment strategy. We propose to examine the comparative effectiveness of initial medical therapy compared to early carotid intervention in a retrospective cohort study. The development of a national cohort of patients with asymptomatic carotid stenosis will further our understanding of the annual rate of stroke and survival in patients treated medically and with revascularization and improve our understanding of who benefits most from intervention.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-HSOD-J (09))
Program Officer
Olson, Jean
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northern California Institute Research & Education
San Francisco
United States
Zip Code
Jones, Christopher W; Misemer, Benjamin S; Platts-Mills, Timothy F et al. (2018) Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study. BMJ Open 8:e019831
Woo, Daniel; Debette, Stephanie; Anderson, Christopher (2017) 20th Workshop of the International Stroke Genetics Consortium, November 3-4, 2016, Milan, Italy: 2016.036 ISGC research priorities. Neurol Genet 3:S12-S18
Keyhani, Salomeh; Cheng, Eric M; Naseri, Ayman et al. (2016) Common Reasons That Asymptomatic Patients Who Are 65 Years and Older Receive Carotid Imaging. JAMA Intern Med 176:626-33
Mowery, Danielle L; Chapman, Brian E; Conway, Mike et al. (2016) Extracting a stroke phenotype risk factor from Veteran Health Administration clinical reports: an information content analysis. J Biomed Semantics 7:26